Skip to main
  1. Stocks
  2. Amneal Pharmaceuticals
  3. Forecast
AMRX

Amneal Pharmaceuticals (AMRX) Stock Forecast & Price Target

Amneal Pharmaceuticals (AMRX) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Amneal Pharmaceuticals is attractive because its Affordable Medicines segment is shifting toward complex generics, injectables, and biosimilars that carry higher barriers to entry, less price erosion, and better margin durability, while still benefiting from a steady 20-30 new launches per year. The Specialty franchise adds another layer of upside, with CREXONT’s rapid uptake, roughly 400 new prescribers monthly, and management’s confidence in a 30%-40% U.S. market share path supporting sales growth, while BREKIYA is already outperforming expectations. In addition, AvKARE’s move away from lower-margin distribution toward higher-margin government sales helped gross margin rise 410bps in 2025, and the company’s 2026 sales and EBITDA estimates were raised to $3.24Bn and $812MM, respectively, reinforcing a durable growth and margin-expansion story.

Bears say

Amneal Pharmaceuticals is viewed negatively because its growth thesis depends on several execution-sensitive catalysts that are already showing strain, including uncertain XOLAIR biosimilar launch timing toward late 2027, second-to-market positioning, and reported biosimilar revenue that declined about 20% in 2025. The company’s operating cash flow outlook was reduced by $25MM at the midpoint to $325MM-$375MM, reflecting finished goods inventory investment and collections shifting into 1Q'27, while CREXONT underperformance and delayed generic launches could weaken the Affordable Medicines segment’s key growth lever. In addition, the expectation that RYTARY faces generic competition in 2027 raises the risk of faster revenue and EBIT erosion, and the need for a step-change in biosimilar growth by 2030 makes the current trend look insufficient.

Amneal Pharmaceuticals (AMRX) has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amneal Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Amneal Pharmaceuticals (AMRX) Analyst Forecast & Price Prediction

Get the latest Amneal Pharmaceuticals (AMRX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Amneal Pharmaceuticals (AMRX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amneal Pharmaceuticals (AMRX) Forecast

Analysts have given Amneal Pharmaceuticals (AMRX) a Buy based on their latest research and market trends.

According to 6 analysts, Amneal Pharmaceuticals (AMRX) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amneal Pharmaceuticals (AMRX)


Amneal Pharmaceuticals (AMRX) Analyst Forecast & Price Prediction

Get the latest Amneal Pharmaceuticals (AMRX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Amneal Pharmaceuticals (AMRX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover AMRX stock data and trends